Ernexa Therapeutics Inc. (ERNA) Amortization of Deferred Charges (2015 - 2026)

Ernexa Therapeutics (ERNA) has 11 years of Amortization of Deferred Charges data on file, last reported at $78000.0 in Q1 2026.

• Quarterly Amortization of Deferred Charges rose 52.94% year-over-year to $78000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $225000.0 (down 95.4% YoY) and the FY2025 annual result came in at $198000.0, down 96.24% from the prior year.
• Amortization of Deferred Charges climbed to $78000.0 in Q1 2026, from $56000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $3.8 million in Q4 2024 to a low of -$186000.0 in Q3 2022.
• A 5-year average of $403466.7 and a median of $84000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges sank 297.87% — and 2024, when it jumped 1417.53%.
• Tracing ERNA's Amortization of Deferred Charges over 5 years: stood at -$186000.0 in 2022, then soared by 234.95% to $251000.0 in 2023, then jumped by 1417.53% to $3.8 million in 2024, then tumbled by 98.53% to $56000.0 in 2025, then surged by 39.29% to $78000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $78000.0 (Q1 2026), $56000.0 (Q4 2025), and $53000.0 (Q3 2025), per Business Quant data.